Haleon is trading at £333.83, down 10.74%, after cutting its 2026 organic revenue growth outlook and reporting a third-quarter miss.
- On October 29, Haleon lowered its 2026 organic revenue growth outlook to around 2.5%, from 3%–5%.
- Third-quarter organic revenue growth was 2.6%, below the 3.2% analyst estimate, as weaker cough, cold and flu demand hurt sales.
- A China raw-material classification change disrupted Centrum OTC imports; Haleon also announced a £500 million buyback.